On Tuesday, 3M Co (NYSE:MMM)’s shares inclined 0.10% to $159.84.
As hospitals and health systems navigate the journey from volume- to value-based health care, 3M Health Information Systems is applying the analytic power of its extensive clinical and claims database to assist providers assess the costs, outcomes and effectiveness of care delivery. The new 3M Health System Performance Suite offers advanced analytic tools to manage the health of populations, measure provider performance, determine total cost of care and succeed under value-based payment.
The latest addition to 3M’s population health administration toolkit, the 3M Health System Performance Suite provides the type of business intelligence that health care organizations need to take part in an Accountable Care Organization (ACO), state initiatives such as Delivery System Reform Incentive Payment (DSRIP) programs, or to understand market share dynamics and address issues such as patient outward migration or network “leakage.”
3M Company operates as a diversified technology company worldwide. Its Industrial segment offers tapes; coated, non-woven, and bonded abrasives; adhesives; ceramics; sealants; specialty materials; filtration products; closure systems for personal hygiene products; acoustic systems products; automotive components; abrasion-resistant films; structural adhesives; and paint finishing and detailing products.
Harley-Davidson Inc (NYSE:HOG)’s shares dropped -0.94% to $58.20.
Harley-Davidson, Inc. (HOG) will release its second-quarter financial results before market hours July 21, 2015. The public is invited to attend an audio webcast from 8-9 a.m. CDT with Matt Levatich, President and Chief Executive Officer, and John Olin, Senior Vice President and Chief Financial Officer, Harley-Davidson, Inc. A downloadable slide presentation will also be accessible, 30 minutes before the call, at http://investor.harley-davidson.com/phoenix.zhtml?c=87981&p=irol-calendar as support to the webcast.
Harley-Davidson, Inc. manufactures cruiser and touring motorcycles. The company operates in two segments, Motorcycles & Related Products and Financial Services. The Motorcycles & Related Products segment designs, manufactures, and sells wholesale street-legal Harley-Davidson motorcycles, in addition to a line of motorcycle parts, accessories, general merchandise, and related services. This segment manufactures six platforms of motorcycles: Touring, Dyna, Softail, Sportster, V-Rod, and Street. It offers motorcycle parts and accessories comprising replacement parts, and mechanical and cosmetic accessories; general merchandise, such as MotorClothes apparel and riding gear; and motorcycle rentals and motorcycle rider training services, in addition to licenses the Harley-Davidson name and other trademarks. This segment sells its products to retail customers through a network of independent dealers primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
At the end of Tuesday’s trade, RXi Pharmaceuticals Corp (NASDAQ:RXII)‘s shares surged 6.52% to $0.490.
RXi Pharmaceuticals Corp (RXII) declared that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi’s novel, self-delivering RNAi platform (sd‑rxRNA®). The patent, titled “Reduced Size Self-Delivering RNAi Compounds,” covers both the composition and methods of use of RXi’s self-delivering platform. The patent, once issued, will be planned to expire in 2031.
In addition, RXi declared that it has also received a Notice of Allowance from the USPTO covering the composition and methods of use for rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). These compounds may be beneficial for the treatment of inflammatory diseases and/or metabolic diseases. RXi’s rxRNAori platform are highly potent RNAi compounds which require delivery vehicles to be taken up by cells and tissues of interest. The patent, once issued, will be planned to expire in 2029.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
Immunomedics, Inc. (NASDAQ:IMMU), ended its Tuesday’s trading session with 1.37% gain, and closed at $4.44.
Immunomedics, Inc. (IMMU) declared an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate (ADC), labetuzumab govitecan, produced encouraging survival results in patients formerly treated with at least one prior irinotecan-containing regimen for their metastatic colorectal cancer (mCRC).
For the 33 patients who received the ADC at the 8 or 10 mg/kg dose levels, the interim median progression-free survival (PFS), a measure of the length of time the patient is living without their disease getting worse from the starting of their labetuzumab govitecan treatments, was 4.4 months, with 22% of these patients still benefiting from their cancer not progressing.
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs comprise epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
